Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

KAIST scientists develop tool to fight drug resistance in cancer

One of the biggest obstacles in cancer treatment is drug resistance in cancer cells. Conventional efforts have focused on identifying new drug targets to eliminate these resistant cells, but such approaches can often lead to even stronger resistance.

8 Jul 2025

New genomic test predicts chemotherapy resistance in cancer patients

Chemotherapy seeks to destroy tumor cells and has been a standard treatment for cancer for decades.

24 Jun 2025

New nanoparticle system improves drug delivery for cancer treatment

Scientists at Xi'an Jiaotong-Liverpool University (XJTLU) and Nanjing University in China have developed a new drug delivery system that could improve how treatments of cancers and other diseases are delivered.

20 Jun 2025

Unmasking Nrf2 as a key driver of treatment resistance in osteosarcoma

A deeper understanding of osteosarcoma, the most common primary malignant bone tumor affecting children and adolescents, is reshaping strategies for overcoming treatment resistance.

20 Apr 2025

New acoustofluidics method transforms intracellular nanoparticle delivery

A recent study published in Engineering presents an innovative acoustofluidics-based approach for intracellular nanoparticle delivery.

7 Mar 2025

Takumi-shaped DNA hydrogels show promise for targeted therapies

Hydrogels are polymeric materials with three-dimensional network structures containing large amounts of water. They serve as sustained-release drug delivery systems as they can encapsulate various bioactive substances, including drugs, antigens, and even cells.

13 Feb 2025

Green tea derived silver nanoparticles show promise against melanoma

Melanoma is a fast-progressing skin cancer characterized by a high mortality rate after metastasis. Local chemotherapy could be considered a therapeutic approach only in stage 0 of progression (in situ melanoma) and in the postoperative phase after surgical removal of suspected skin lesions.

3 Feb 2025

NUS researchers enhance chemotherapy with magnetic field pulses

Researchers at the National University of Singapore (NUS) have developed a non-invasive method to improve the effectiveness of chemotherapy while reducing its harmful side effects.

6 Jan 2025

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

11 Dec 2024

Serum protein panel test can help identify cardiomyopathy risk in childhood cancer survivors

Early disease detection is beneficial for securing the best possible outcomes for patients. But finding noninvasive, effective ways to predict disease risk is a tremendous challenge.

3 Dec 2024

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

Tiny particles deliver combined heat and chemotherapy to tumors

Patients with late-stage cancer often have to endure multiple rounds of different types of treatment, which can cause unwanted side effects and may not always help.

29 Oct 2024

New drug WNTinib shows promise in treating pediatric liver cancer

A new drug called WNTinib can delay the growth of tumors and improve survival in hepatoblastoma, a type of liver cancer that occurs in young children.

22 Oct 2024

New insights into the mechanisms of efavirenz-induced neurotoxicity

Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients' quality of life over time. It causes neuropsychiatric disorders and neurocognitive impairment in roughly 50 percent of patients. The drug is associated with abnormal lipid levels in blood plasma, but the molecular mechanisms responsible for negative clinical observations are unknown.

18 Sep 2024

2-bromopalmitate reduces senescence phenotype in human cells by modulating palmitoylation

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 16 on August 23, 2024, entitled, "2-Bromopalmitate treatment attenuates senescence phenotype in human adult cells - possible role of palmitoylation."

11 Sep 2024